Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker BCYC
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Steven Boyd | 3.40M | 6.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Armistice Capital, LLC | 3.40M | 6.7% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Steven Boyd | 3.40M | 6.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Armistice Capital, LLC | 3.40M | 6.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | John Helmers | 3.31M | 6.6% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Long Focus Capital Management, LLC | 3.31M | 6.6% | SCHEDULE 13G ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Raymond Debbane | 1.56M | 3.1% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Ulys, L.L.C. | 192,296 | 0.4% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Avicenna Life Sci Master GP LLC | 192,296 | 0.4% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Avicenna Life Sci Master Fund LP | 192,296 | 0.4% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Siren, L.L.C. | 1.37M | 2.7% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Invus Global Management, LLC | 1.37M | 2.7% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Invus Public Equities Advisors, LLC | 1.37M | 2.7% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Invus Public Equities, L.P. | 1.37M | 2.7% | SCHEDULE 13G/A ↗ |
| Mar 4, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Westfield Capital Management Company, L.P. | — | 0.0% | SCHEDULE 13G/A ↗ |
| Mar 3, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Raymond Debbane | 3.15M | 6.3% | SCHEDULE 13G ↗ |
| Mar 3, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Ulys, L.L.C. | 429,342 | 0.9% | SCHEDULE 13G ↗ |
| Mar 3, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Avicenna Life Sci Master GP LLC | 429,342 | 0.9% | SCHEDULE 13G ↗ |
| Mar 3, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Avicenna Life Sci Master Fund LP | 429,342 | 0.9% | SCHEDULE 13G ↗ |
| Mar 3, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Siren, L.L.C. | 2.72M | 5.4% | SCHEDULE 13G ↗ |
| Mar 3, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Invus Global Management, LLC | 2.72M | 5.4% | SCHEDULE 13G ↗ |
| Mar 3, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Invus Public Equities Advisors, LLC | 2.72M | 5.4% | SCHEDULE 13G ↗ |
| Mar 3, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Invus Public Equities, L.P. | 2.72M | 5.4% | SCHEDULE 13G ↗ |
| Mar 3, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Westfield Capital Management Company, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Mar 3, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Westfield Capital Management Company, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 18, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Steven Boyd | 3.24M | 6.5% | SCHEDULE 13G ↗ |
| Feb 18, 2026 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Armistice Capital, LLC | 3.24M | 6.5% | SCHEDULE 13G ↗ |
| Feb 11, 2026 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Westfield Capital Management Company, L.P. | 3.02M | 6.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Steven Boyd | 359,703 | 5.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Armistice Capital, LLC | 359,703 | 5.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | David Kroin | 1.20M | 2.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Deep Track Biotechnology Master Fund, Ltd. | 1.20M | 2.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Deep Track Capital, LP | 1.20M | 2.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Steven A. Cohen | 1.86M | 3.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Point72 Capital Advisors, Inc. | 1.86M | 3.9% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Point72 Asset Management, L.P. | 1.86M | 3.9% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Steven Boyd | 2.67M | 5.6% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Armistice Capital, LLC | 2.67M | 5.6% | SCHEDULE 13G ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | David Kroin | 2.82M | 5.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Deep Track Biotechnology Master Fund, Ltd. | 2.82M | 5.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Deep Track Capital, LP | 2.82M | 5.7% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Steven A. Cohen | 3.74M | 7.8% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Point72 Capital Advisors, Inc. | 3.74M | 7.8% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Point72 Asset Management, L.P. | 3.74M | 7.8% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | David Kroin | 3.33M | 6.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Deep Track Biotechnology Master Fund, Ltd. | 3.33M | 6.7% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | BCYC Bicycle Therapeutics plc | Deep Track Capital, LP | 3.33M | 6.7% | SCHEDULE 13G/A ↗ |
| Feb 11, 2025 | SCHEDULE 13G | BCYC Bicycle Therapeutics plc | Westfield Capital Management Company, L.P. | 2.61M | 5.5% | SCHEDULE 13G ↗ |
48 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:44 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances